Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.
Ajulemic acid (AJA) is a synthetic analog of the tetrahydrocannabinol (THC) metabolite THC-11-oic acid; THC is a major active ingredient of the drug marijuana derived from the plant cannabis. AJA has potent analgesic and anti-inflammatory activity without the psychotropic action of THC. Unlike the nonsteroidal anti-inflammatory drugs, AJA is not ulcerogenic at therapeutic doses, making it a promising anti-inflammatory drug. However, the mechanism of AJA action remains unknown. Here we report that AJA binds directly and specifically to the peroxisome proliferator-activated receptor gamma (PPARgamma), a pharmacologically important member of the nuclear receptor superfamily. Functional assay indicates that AJA activates the transcriptional activity of both human and mouse PPARgamma at pharmacological concentrations. Activation of PPARgamma by AJA requires the AF-2 helix of the receptor, suggesting that AJA activates PPARgamma through the ligand-dependent AF-2 function. AJA binding consistently enables PPARgamma to recruit nuclear receptor coactivators. In addition, we show that AJA inhibits interleukin-8 promoter activity in a PPARgamma-dependent manner, suggesting a link between the anti-inflammatory action of AJA and the activation of PPARgamma. Finally, we find that AJA treatment induces differentiation of 3T3 L1 fibroblasts into adipocytes, a process mediated by PPARgamma. Together, these data indicate that PPARgamma may be a molecular target for AJA, providing a potential mechanism for the anti-inflammatory action of AJA, and possibly other cannabinoids. These studies also implicate other potential therapeutic actions of AJA through PPARgamma activation in multiple signaling pathways.
Liu
Jilin
J
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Li
Hui
H
Burstein
Sumner H
SH
Zurier
Robert B
RB
Chen
J Don
JD
D017667:Adipocytes / Q000166:cytology / Q000187:drug effects; D001665:Binding Sites; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D013759:Dronabinol / Q000031:analogs & derivatives / Q000494:pharmacology*; D006801:Humans; D016209:Interleukin-8 / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000502:physiology; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000502:physiology; D014157:Transcription Factors / Q000819:agonists* / Q000502:physiology
D016209:Interleukin-8; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D013759:Dronabinol; C471849:lenabasum